Klinische Forschung Hamburg GmbH

Research at Klinische Forschung Hamburg focuses on cardiovascular diseases such as atherosclerotic disease, atrial fibrillation, heart failure, and elevated lipoprotein(a). The trials aim to evaluate new treatments that lower stroke risk, improve heart function, and reduce harmful cholesterol levels.

• Atrial fibrillation anticoagulation alternatives
• Combination therapies for heart failure
• Lipoprotein(a) lowering agents

These studies seek to enhance long‑term cardiovascular health for patients in Germany and beyond.

The site conducts investigations into digestive system disorders, notably irritable bowel syndrome and diarrhea‑dominant subtypes. Objectives include testing novel compounds and probiotic approaches to relieve abdominal pain and improve bowel regularity.

• Probiotic treatment for IBS‑D
• Medication targeting IBS‑M symptoms

Findings aim to provide better symptom control for individuals suffering from chronic gastrointestinal issues.

Studies address female urogenital conditions such as androgenetic alopecia and hormonal hair loss. Research evaluates oral and topical therapies to promote hair growth and restore normal hair cycles.

• Oral minoxidil combined with topical vehicle
• Topical treatments for hormone‑related hair loss

The goal is to expand safe and effective options for women experiencing hair thinning.

Clinical work includes trials on disorders linked to hormone imbalance, for example sleep disturbances linked to menopause. Investigations test agents that modulate hormonal pathways to improve sleep quality.

• Elinzanetant for menopausal sleep issues
• Hormone‑targeted therapies for insomnia

Results could lead to new non‑hormonal treatments for women with menopause‑related sleep problems.

Research explores immune‑mediated conditions such as multiple sclerosis and chronic inflammatory pain. Trials assess biologic agents and anti‑inflammatory compounds for safety and disease‑modifying effects.

• Ocrelizumab biosimilar pharmacokinetic comparison
• Anti‑inflammatory protein XPro1595 in early Alzheimer’s disease

These efforts aim to broaden therapeutic choices for patients with autoimmune and neuroinflammatory disorders.

The facility runs studies on musculoskeletal disorders including chronic low back pain, osteoarthritis, and bone‑related conditions. Projects evaluate pain‑relieving drugs and weight‑loss agents that may reduce joint stress.

• Dose‑response study of VER‑01 for low back pain
• Orforglipron combined with empagliflozin for osteoarthritis pain
• MET097 weekly dosing for overweight and obesity

Outcomes are intended to improve functional ability and quality of life for patients with chronic musculoskeletal pain.

Investigations target nervous system ailments such as early Alzheimer’s disease, cognitive impairment after COVID‑19, and multiple sclerosis. The purpose is to test agents that may protect neurons and enhance cognitive performance.

• XPro1595 for early Alzheimer’s disease
• Ginkgo biloba extract EGb 761 for post‑COVID cognitive deficits
• ABP 692 biosimilarity to ocrelizumab in relapsing‑remitting MS

Successful therapies could slow disease progression and preserve mental function.

The site examines metabolic conditions including obesity, type 2 diabetes, and elevated LDL‑cholesterol. Trials focus on novel oral agents that promote weight loss and improve lipid profiles.

• Orforglipron for obesity and overweight
• AZD0780 impact on LDL‑C reduction
• MET097 for weight management in obese participants

These studies aim to provide additional tools for managing metabolic health and reducing cardiovascular risk.

Research includes respiratory disorders such as chronic obstructive pulmonary disease, refractory chronic cough, and viral infections. Objectives are to assess symptom relief and vaccine efficacy against influenza and RSV.

• BLU‑5937 for refractory chronic cough
• mRNA‑1010 influenza vaccine safety and immunogenicity
• IVX‑A12 RSV and hMPV vaccine in older adults

Findings could lead to better management of chronic lung conditions and improved protection from seasonal viruses.

Trials address skin and connective tissue issues such as allergic rhinitis and seasonal allergic reactions. Studies test allergen‑specific immunotherapy and antihistamine alternatives for symptom control.

• PQ Birch for birch pollen‑induced allergic rhinitis
• Silexan for mild to moderate major depressive disorder with skin‑related symptom overlap

The goal is to improve quality of life for individuals affected by allergic and dermatologic conditions.

The facility conducts work on viral infections including influenza, respiratory syncytial virus, and human metapneumovirus. Clinical programs evaluate new vaccine candidates and antiviral strategies.

• mRNA‑1010 influenza vaccine comparative study
• IVX‑A12 vaccine preventing RSV and hMPV lower respiratory disease

These projects aim to enhance prevention and reduce disease burden from common respiratory viruses.

Research explores behavioral health aspects such as sleep‑wake cycle disorders and alcohol use. Studies examine pharmacologic and behavioral interventions to normalize sleep patterns and reduce harmful drinking.

• Tasimelteon for delayed sleep‑wake phase disorder
• Brenipatide for moderate‑to‑severe alcohol use disorder

Outcomes could provide new options for patients struggling with sleep regulation and substance dependence.

Clinical investigations target mental health conditions including major depressive disorder, anxiety, and mood disturbances. Trials assess novel antidepressants, adjunctive therapies, and cannabinoid aerosols for mood improvement.

• NMRA‑335140 for major depressive disorder
• Aticaprant as adjunctive therapy to prevent depression relapse
• Medical cannabis aerosol for diabetic peripheral neuropathic pain and mood

The aim is to expand effective treatment options for individuals living with depression and related disorders.